UK artificial intelligence specialist Exscientia has topped up its coffers with a $60 million Series C funding round that will be used to advance projects into clinical trials.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
